Chronic Lymphocyticleukemia Small Lymphocytic Lymphoma — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for chronic lymphocyticleukemia small lymphocytic lymphoma. 9 active patents protecting 1 drugs from 1+ originators. First major cliff: 2026. Daily refresh.

1
Approved drugs
9
Active US patents
53/100
Avg vulnerability
$3.1B
Annual revenue covered

Originators in Chronic Lymphocyticleukemia Small Lymphocytic Lymphoma

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

AstraZeneca 9 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating chronic lymphocyticleukemia small lymphocytic lymphoma. Each bar = one year. Y-axis scaled to peak year (3 patents).

1
26
3
32
3
35
2
36

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Calquence
ACALABRUTINIB
 AstraZeneca 9 53 $3.1B 2026-11-24

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11166951 Calquence method of use 75 2035-08-11
11771696 Calquence method of use 70 2035-01-21
10239883 Calquence method of use 62 2032-07-11
9758524 Calquence method of use 62 2032-07-11
10272083 Calquence method of use 62 2035-01-21
10167291 Calquence method of use 62 2036-07-01
9796721 Calquence method of use 62 2036-07-01
7459554 Calquence composition of matter 22 2026-11-24
9290504 Calquence composition of matter 4 2032-07-11

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9290504 Calquence composition of matter 4 2032-07-11
7459554 Calquence composition of matter 22 2026-11-24
9796721 Calquence method of use 62 2036-07-01
10167291 Calquence method of use 62 2036-07-01
10272083 Calquence method of use 62 2035-01-21
10239883 Calquence method of use 62 2032-07-11
9758524 Calquence method of use 62 2032-07-11
11771696 Calquence method of use 70 2035-01-21
11166951 Calquence method of use 75 2035-08-11

Related